Gefapixant leads to modest improvements in cough

that compared gefapixant with placebo or two or more doses of gefapixant with or without placebo. The primary analysis included nine RCTs with 2,980 patients.

The researchers found that gefapixant had small effects on awake cough frequency , cough severity , and cough-specific compared with placebo. However, an important increase in treatment-related adverse events and taste-related adverse events was probably caused by gefapixant versus placebo. Small effects on taste-related adverse events were suggested for gefapixant versus placebo based on high-certainty evidence.

"Although gefapixant did appear to have a small effect on improving cough compared with placebo, the effects were marginal when compared with the large, favorable effects of alone," Richard S. Irwin, M.D., and J. Mark Madison, M.D., from the University of Massachusetts Chan Medical School in Worcester, write in an accompanying editorial.More information:

Elena Kum et al, Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough,

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Hospital admissions for COPD has increased substantially, especially in women and younger peopleAnnual hospital admissions for chronic obstructive pulmonary disease (COPD) in Canada increased 69% since 2002, especially in females and people under age 65, according to new research in CMAJ (Canadian Medical Association Journal).
Source: medical_xpress - 🏆 101. / 51 Read more »